Browsing tag:

Warfarin


As an effectual oral factor Xa inhibitor, Edoxaban is FDA approved as a novel anticoagulant therapy in the U.S. as an anticoagulant in several capacities: To reduce the risk with of both systemic embolism and stroke in patients afflicted with atrial fibrillation (AF), which is not related to heart valve problems. As a treatment for patients[…]

Read More

The FDA offered a nod of approval for the use of Apixaban when treating patients post orthopedic surgery. This recent endorsement of Bristol Myers’ brand name drug Eliquis {Apixaban} is timely and encouraging, with a little over one million orthopedic surgeries performed in the U.S. each year. The high risk of deep vein thrombosis or[…]

Read More

Diclofenac Potassium CAS# 15307-81-0, also known as the brand name Zipsor, netted an astounding three million dollars in sales for the first quarter of 2013. Depomed Incorporated, who markets the NSAID, recently reported their better than expected financials regarding this efficacious treatment for arthritis and pain. The patent for Zipsor expires on July 15, 2019,[…]

Read More

Exemplary news on July 1, 2013 revealed that Apixaban, known as the brand name Eliquis, had achieved its primary goal in studies. Marketed by both Pfizer and Bristol-Myers Squibb, Apixaban is an effective anticoagulant that has undergone strenuous testing, based on data from a recently released study coined AMPLIFY. Results from this comprehensive study were[…]

Read More

The FDA exclusivity for Plavix (clopidogrel) ended on May 17, 2012, while patent protection expires January 31, 2014. This exciting news brings Clopidogrel CAS# 113665-84-2, to the forefront of pharmaceutical news. With sales of Plavix generating billions of dollars for Bristol-Myers Squibb/Sanofi Pharmaceuticals, researchers are clamoring to create generic options of clopidogrel. As an antiplatelet[…]

Read More

Gefitinib, CAS number 184475-35-2, is also known as the brand Iressa, which is marketed by AstraZeneca and Teva. Gefitinib is approved by the FDA to treat malignant and/or advanced non small cell lung cancer. Iressa has been shown to be effective in about 10% of clinical trial patients. LGM Pharma supplies gefitinib for R&D purposes,[…]

Read More

Apixaban, CAS number 503612-47-3, is showing itself to be a viable option for patients with atrial fibrillation who are in need of an anticoagulant. In two studies, ARISTOTLE and AVERROES, which included over 24,000 patients, Apixaban (Eliquis) showed statistically significant superiority to Warfarin.  A 21%  lower stroke risk for patients with atrial fibrillation was an[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service